Press Releases

Cannasat Therapeutics Inc. Announces $600,000 Financing

MarketWire, February 6, 2022

Toronto, Ontario - Cannasat Therapeutics Inc. (CTH : TSXV) announced today that it intends to conduct a non-brokered  private placement  of up to 6,000,000 Units of Cannasat at a price of $0.10 per Unit, for aggregate gross proceeds of up to $600,000 (the “Offering”).  Each Unit will consist of one common share and one-half of one share purchase warrant.  Each whole share purchase warrant shall entitle the holder to acquire one common share at a price of $0.15 for a period of 24 months from the date of closing of the Offering.

The proceeds from the Offering will be used to fund Cannasat’s ongoing CAT 310 and CAT 320 research and development activities as well as working capital and general corporate services.

It is intended that the Offering will be made to “accredited investors” in the Provinces of Ontario, Alberta and British Columbia.

The Offering and closing of the financing is subject to regulatory approval from the TSX Venture Exchange Inc.



Cannasat is a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia. Cannasat currently has two new drugs in its pipeline: CAT 310 and CAT 320. CAT 310 is currently in Phase I clinical trials and CAT 320 is scheduled to begin Phase I trials in mid-2009.  More information about Cannasat (CTH : TSXV) is available at



Cannasat Therapeutics Inc.
Andrew Williams
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]



Certain statements in this release may constitute forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors, which may cause actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements.

The TSX Venture Exchange Inc. has not reviewed and do not accept responsibility for the adequacy or accuracy of this press release.

Horizonatal Rule
About CynapsusLine SeperationAPL-130277 ProductLine SeperationParkinson's DiseaseLine SeperationInvestor RelationsLine SeperationContact & LegalLine Seperation

Copyright 2016, Cynapsus Therapeutics Inc.
All rights reserved.

Traded on